16,760 Shares in AtriCure, Inc. (NASDAQ:ATRC) Purchased by Bryce Point Capital LLC

Bryce Point Capital LLC acquired a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 16,760 shares of the medical device company's stock, valued at approximately $512,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blue Trust Inc. lifted its position in AtriCure by 1.8% during the fourth quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock valued at $414,000 after buying an additional 265 shares in the last quarter. Perkins Capital Management Inc. lifted its holdings in shares of AtriCure by 1.3% during the 4th quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock valued at $927,000 after acquiring an additional 400 shares in the last quarter. Truist Financial Corp boosted its position in AtriCure by 2.6% during the 4th quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock worth $480,000 after purchasing an additional 403 shares during the period. Franklin Resources Inc. increased its holdings in AtriCure by 0.9% in the 3rd quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock valued at $1,569,000 after purchasing an additional 484 shares in the last quarter. Finally, LPL Financial LLC raised its position in AtriCure by 5.4% in the fourth quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock valued at $350,000 after purchasing an additional 584 shares during the period. 99.11% of the stock is owned by institutional investors and hedge funds.

Remove Ads

AtriCure Stock Up 8.1 %

Shares of ATRC stock traded up $2.49 during trading hours on Wednesday, hitting $33.10. 677,599 shares of the company were exchanged, compared to its average volume of 669,901. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -34.84 and a beta of 1.65. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The business's 50-day simple moving average is $36.34 and its two-hundred day simple moving average is $34.23. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.20% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ATRC shares. JPMorgan Chase & Co. decreased their target price on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, March 27th. BTIG Research reaffirmed a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Stifel Nicolaus boosted their target price on shares of AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Piper Sandler raised their price target on shares of AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Finally, Oppenheimer boosted their price objective on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $49.44.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.